Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Rheumatology Therapeutics Market to 2018 - Introduction
2.1 Introduction
3 Rheumatology Therapeutics Market to 2018 - Market Overview
3.1 Introduction
3.1.1 Revenue
3.1.2 Annual Cost of Treatment
3.1.3 Treatment Usage Pattern
4 Rheumatology Therapeutics Market to 2018 - Geographical Landscape Revenue Analysis by Geography
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Treatment
4.1.3 Treatment Usage Patterns
4.2 Top Five Countries of Europe
4.2.1 Introduction
4.2.2 Revenue
4.2.3 Annual Cost of Treatment
4.2.4 Treatment Usage Patterns
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Patterns
4.4 Australia
4.4.1 Overview of Rheumatology Market
4.5 China
4.5.1 Revenue
4.6 India
4.6.1 Overview of Rheumatology Market
5 Rheumatology Therapeutics Market to 2018 - Therapeutic Landscape
5.1 Rheumatoid Arthritis Therapeutics Market
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Revenue by Country
5.1.4 Annual Cost of Treatment
5.1.5 Treatment Usage Pattern
5.1.6 Treatment Flow Algorithm
GBIHC240MR / Published DEC 2012
Page 2
Rheumatology Therapeutics Market to 2018 - Increasing Uptake of
Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur
Growth © GBI Research. This report is a licensed product and is not to be copied, reproduced,
shared or resold in any form
5.1.7 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market
5.2 Osteoarthritis Therapeutics Market
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Revenue by Country
5.2.4 Annual Cost of Treatment
5.2.5 Treatment Flow Algorithm
5.2.6 Treatment Usage Pattern
5.2.7 Drivers and Barriers for the Osteoporosis Therapeutics Market
5.3 Gout Therapeutics Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Revenue by Country
5.3.4 Annual Cost of Treatment
5.3.5 Treatment Usage Pattern
5.3.6 Treatment Flow Algorithm
5.3.7 Drivers and Barriers for the Gout Therapeutics Market
5.4 Systemic Lupus Erythematosus Therapeutics Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Treatment
5.4.4 Treatment Usage Pattern
5.4.5 Treatment Flow Algorithm
5.4.6 Drivers and Barriers for Systemic Lupus Erythematosus Therapeutics Market
6 Rheumatology Therapeutics Market to 2018 - Pipeline Analysis
6.1 Pipeline Assessment by Clinical Phase of Development
6.2 Key R&D Trends and Future Outlook
6.3 Profiles of Promising Molecules
6.3.1 Tofacitinib
6.3.2 Fostamatinib
6.3.3 LY2127399 (tabalumab)
6.3.4 Naproxcinod
6.3.5 RDEA594 (lesinurad)
6.3.6 BCX4208
6.3.7 Epratuzumab
6.3.8 Lupuzor
6.3.9 Atacicept
7 Rheumatology Therapeutics Market to 2018 - Competitive Landscape
7.1 Abbott
7.1.1 Overview
7.1.2 Major Marketed Products
7.1.3 SWOT Analysis
7.2 Amgen
7.2.1 Overview
7.2.2 Major Marketed Products
7.2.3 SWOT Analysis
7.3 Pfizer
7.3.1 Overview
7.3.2 Major Marketed Products
7.3.3 SWOT Analysis
GBIHC240MR / Published DEC 2012
Page 3
Rheumatology Therapeutics Market to 2018 - Increasing Uptake of
Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur
Growth © GBI Research. This report is a licensed product and is not to be copied, reproduced,
shared or resold in any form
7.4 Janssen Biotech
7.4.1 Overview
7.4.2 Major Marketed Products
7.4.3 SWOT Analysis
7.5 Merck
7.5.1 Overview
7.5.2 Major Marketed Products
7.5.3 SWOT Analysis
8 Rheumatology Therapeutics Market to 2018 - Strategic Consolidations
8.1 Overview
8.1.1 Deals by Type of Agreement
8.1.2 Deals by Year
8.1.3 Deals by Geography
8.1.4 Profiling of Major Deals
9 Rheumatology Therapeutics Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.5 Therapeutic Landscape
9.5.1 Epidemiology-based Forecasting
9.5.2 Market Size by Geography
9.6 Geographical Landscape
9.7 Pipeline Analysis
9.8 Competitive Landscape
9.8.1 Expert Panel Validation
9.9 Contact Us
9.10 Disclaimer